Phathom Pharmaceuticals, Inc.
PHAT
$14.61
-$0.14-0.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -274.55M | -330.15M | -345.79M | -334.33M | -339.45M |
| Total Depreciation and Amortization | 698.00K | 733.00K | 758.00K | 795.00K | 787.00K |
| Total Amortization of Deferred Charges | 2.83M | 2.65M | 2.41M | 2.19M | 2.13M |
| Total Other Non-Cash Items | 71.25M | 74.60M | 77.13M | 79.87M | 95.00M |
| Change in Net Operating Assets | -25.46M | -22.52M | -17.19M | -15.30M | -5.59M |
| Cash from Operations | -225.23M | -274.69M | -282.68M | -266.77M | -247.11M |
| Capital Expenditure | -147.00K | -164.00K | -113.00K | -135.00K | -605.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -147.00K | -164.00K | -113.00K | -135.00K | -605.00K |
| Total Debt Issued | 24.75M | 24.75M | 49.50M | 59.40M | 246.64M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.67M | 123.43M | 123.37M | 123.37M | 122.08M |
| Repurchase of Common Stock | -564.00K | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25.86M | 148.18M | 172.87M | 182.77M | 368.72M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -199.52M | -126.67M | -109.92M | -84.13M | 121.01M |